NCT05722873

Brief Summary

Caloric restriction has beneficial metabolic effects in humans including weight loss and improvement in blood pressure and lipid levels. Intermittent fasting has emerged as a popular alternative to caloric restriction as it does not require daily adherence to a dietary protocol, but whether the benefits of fasting protocols are dependent on weight loss is not known. In this study, the investigators will explore the metabolic effects of fasting and evaluate whether these effects, including negative effects on bone metabolism, are independent of weight loss.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
26mo left

Started Oct 2023

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress54%
Oct 2023Jun 2028

First Submitted

Initial submission to the registry

January 27, 2023

Completed
14 days until next milestone

First Posted

Study publicly available on registry

February 10, 2023

Completed
9 months until next milestone

Study Start

First participant enrolled

October 25, 2023

Completed
4.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2028

Last Updated

August 7, 2025

Status Verified

August 1, 2025

Enrollment Period

4.7 years

First QC Date

January 27, 2023

Last Update Submit

August 2, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Triglyceride carbon content and degree of saturation

    Change in triglyceride carbon content and degree of saturation (% variation explained by both carbon number and double bond number in a regression model) between Baseline and Final Intervention visits

    Baseline, 3 months

  • Trabecular bone microarchitecture

    Change in trabecular bone volume fraction at the radius between Baseline and Final Intervention visits

    Baseline, 3 months

Secondary Outcomes (1)

  • Insulin sensitivity

    Baseline, 3 months

Study Arms (3)

Fasting

EXPERIMENTAL

Subjects will fast one-day per week for 12 weeks

Behavioral: Fasting arm

Fasting with weight maintenance

EXPERIMENTAL

Subjects will fast one-day per week for 12 weeks and maintain body weight

Behavioral: Fasting armBehavioral: Weight maintenance

Counseling

PLACEBO COMPARATOR

Subjects will be counseled on optimal diet and activity recommendations to maintain/achieve a normal BMI (standard of care)

Behavioral: Counseling

Interventions

Fasting armBEHAVIORAL

Study participants will fast one day per week for 12 weeks

FastingFasting with weight maintenance

Study participants will be counseled to maintain body weight

Fasting with weight maintenance
CounselingBEHAVIORAL

Study participants will be counseled on optimal diet and activity recommendations for maintaining/achieving a normal BMI

Counseling

Eligibility Criteria

Age21 Years - 45 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Men and women, ages 21-45 years
  • BMI of at least 21 kg/m2 and up to and including BMI of 29 kg/m2
  • Normal thyroid function
  • Regular menses (women)
  • At least one first-degree relative with type 2 diabetes (T2D) and/or history of gestational diabetes

You may not qualify if:

  • Any chronic diseases including hypertension and Type 2 diabetes mellitus
  • Indication for lipid-lowering therapy in non-diabetics, using the more stringent AHA guideline cutoff (LDL\>190 or an estimated 10-year ASCVD risk of \>7.5%)
  • Chronic medications, including oral contraceptive pills
  • Pregnant and/or breastfeeding
  • History of an eating disorder
  • OH vitamin D level \< 20 ng/mL
  • Active substance abuse, including alcohol
  • Subjects with a prior history of intermittent fasting
  • The study physician feels that the subject may not be able to safely complete the protocol or may place themselves at risk by undergoing the protocol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Pittsburgh

Pittsburgh, Pennsylvania, 15213, United States

RECRUITING

Related Publications (1)

  • Quaytman JA, David NL, Venugopal S, Amorim T, Beatrice B, Toledo FGS, Miller RG, Steinhauser ML, Fazeli PK. Intermittent fasting for systemic triglyceride metabolic reprogramming (IFAST): Design and methods of a prospective, randomized, controlled trial. Contemp Clin Trials. 2024 Nov;146:107698. doi: 10.1016/j.cct.2024.107698. Epub 2024 Sep 17.

MeSH Terms

Interventions

Body Weight MaintenanceCounseling

Intervention Hierarchy (Ancestors)

Body WeightBody SizeGrowthGrowth and DevelopmentPhysiological PhenomenaMental Health ServicesBehavioral Disciplines and ActivitiesCommunity Health ServicesHealth ServicesHealth Care Facilities Workforce and Services

Study Officials

  • Pouneh Fazeli, MD

    University of Pittsburgh

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Pouneh Fazeli, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Randomized, controlled study
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Medicine

Study Record Dates

First Submitted

January 27, 2023

First Posted

February 10, 2023

Study Start

October 25, 2023

Primary Completion (Estimated)

June 30, 2028

Study Completion (Estimated)

June 30, 2028

Last Updated

August 7, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will share

Deidentified information will be shared upon request.

Shared Documents
STUDY PROTOCOL, ICF
Time Frame
Beginning 12 months after publication. No end date.
Access Criteria
Researchers who wish to access deidentified data.

Locations